Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage

by Zacks Equity Research

ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.

Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression

by Zacks Equity Research

Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

Andrew Rocco headshot

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

by Andrew Rocco

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe

by Zacks Equity Research

Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.

Anavex's (AVXL) Lead Alzheimer's Drug Meets Study Goal

by Zacks Equity Research

Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.

Sarepta Therapeutics (SRPT) Up 17.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal

by Kinjel Shah

Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.

Repligen (RGEN) Up 4.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Lilly's (LLY) Donanemab Betters Biogen's Alzheimer's Drug

by Zacks Equity Research

Data from a phase III early symptomatic Alzheimer's disease study shows that Eli Lilly's (LLY) donanemab leads to a significant reduction of amyloid buildup in the brain and P-tau in the blood after six months.

Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects

by Zacks Equity Research

Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adverse events like brain hemorrhage.

Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion

by Zacks Equity Research

Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations.

Biogen (BIIB) Down on Report of Death in Alzheimer's Study

by Zacks Equity Research

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.

CinCor (CINC) Tanks Due to Dismal Data on Hypertension Drug

by Zacks Equity Research

CinCor (CINC) plummets as its phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension, fails to meet its primary endpoint.

Gilead (GILD), RCUS Announce Positive Data From NSCLC Study

by Zacks Equity Research

Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC).

Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

by Zacks Equity Research

Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.

Why Is BioMarin (BMRN) Up 14.1% Since Last Earnings Report?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Biogen Inc. (BIIB) Up 8.2% Since Last Earnings Report?

by Zacks Equity Research

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novartis (NVS) Set to Advance Malaria Drug Into Phase III

by Zacks Equity Research

Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.

BIIB or RGEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BIIB vs. RGEN: Which Stock Is the Better Value Option?

Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer

by Zacks Equity Research

Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer.

Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AMN Healthcare Services (AMN) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.

Novartis (NVS) Reportedly Looking to Sell Its Business Units

by Zacks Equity Research

Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.

Is Biogen (BIIB) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines

by Zacks Equity Research

Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.

Roche (RHHBY) AD Study Failure Puts Spotlight on BIIB & Others

by Zacks Equity Research

Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.